KRAS and non-small cell lung carcinoma: Our immunoblot data show that although there is a dose-dependent reduction of ppERK in BxPC-3 and H522, control cell lines for PDAC and NSCLC, respectively, ppERK level was initially elevated at 10 μM and showed a trend of decrease at higher concentrations in K-Ras-dependent cell lines (Fig 1F).